Amphastar Pharmaceuticals, Inc. $AMPH Stake Raised by Cwm LLC

Cwm LLC boosted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 574.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,502 shares of the company’s stock after acquiring an additional 3,834 shares during the quarter. Cwm LLC’s holdings in Amphastar Pharmaceuticals were worth $103,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC raised its position in Amphastar Pharmaceuticals by 62.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,624 shares of the company’s stock worth $290,000 after acquiring an additional 4,855 shares in the last quarter. IFP Advisors Inc raised its position in Amphastar Pharmaceuticals by 75.7% in the second quarter. IFP Advisors Inc now owns 2,035 shares of the company’s stock worth $52,000 after acquiring an additional 877 shares in the last quarter. Polaris Capital Management LLC raised its position in Amphastar Pharmaceuticals by 14.0% in the second quarter. Polaris Capital Management LLC now owns 35,100 shares of the company’s stock worth $806,000 after acquiring an additional 4,300 shares in the last quarter. State of Alaska Department of Revenue raised its position in Amphastar Pharmaceuticals by 5.3% in the second quarter. State of Alaska Department of Revenue now owns 21,892 shares of the company’s stock worth $502,000 after acquiring an additional 1,111 shares in the last quarter. Finally, CX Institutional raised its position in Amphastar Pharmaceuticals by 220.5% in the second quarter. CX Institutional now owns 263,283 shares of the company’s stock worth $6,045,000 after acquiring an additional 181,136 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 3.4%

NASDAQ:AMPH opened at $25.50 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96. The stock’s 50-day moving average is $26.78 and its two-hundred day moving average is $25.23. The stock has a market cap of $1.19 billion, a PE ratio of 9.55 and a beta of 0.75.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Bank of America boosted their price objective on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 26th. Zacks Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Amphastar Pharmaceuticals in a report on Wednesday, October 22nd. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday, August 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.